. 2026 Jan 12;12:1722081. doi: 10.3389/fnut.2025.1722081

Table 9.

Comparison of pDC activity (middle-aged participants).

Marker	Week	Group	Measured value		Change from baseline
Marker	Week	Group	Mean ± SD	p-value	Mean ± SD	p-value
CD86	0	Placebo	3,078.0 ± 698.6	0.966	—	—
	0	LG2055	3,072.9 ± 648.1	0.966	—	—
	4	Placebo	3,222.3 ± 698.7	0.484	144.3 ± 526.6	0.449
	4	LG2055	3,143.7 ± 552.9	0.484	70.8 ± 567.2	0.449
	8	Placebo	3,416.5 ± 705.5	0.732	338.5 ± 608.9	0.755
	8	LG2055	3,378.4 ± 529.8	0.732	305.5 ± 584.3	0.755
	12	Placebo	3,773.9 ± 770.9	0.277	695.8 ± 643.3	0.240
	12	LG2055	3,641.6 ± 574.0	0.277	568.8 ± 566.5	0.240
HLA-DR	0	Placebo	76,911.6 ± 15,236.7	0.698	—	—
	0	LG2055	78,043.3 ± 17,673.3	0.698	—	—
	4	Placebo	80,417.3 ± 16,095.8	0.857	3,505.7 ± 6,418.5	0.628
	4	LG2055	80,978.6 ± 19,062.1	0.857	2,935.4 ± 6,852.4	0.628
	8	Placebo	82,223.5 ± 16,809.6	0.645	5,311.9 ± 6,172.1	0.038^*
	8	LG2055	80,833.7 ± 17,170.8	0.645	2,790.4 ± 7,392.5	0.038^*
	12	Placebo	85,556.5 ± 15,591.4	0.958	8,644.9 ± 7,372.6	0.334
	12	LG2055	85,395.5 ± 18,519.9	0.958	7,352.2 ± 7,693.0	0.334
CD80	0	Placebo	3,787.4 ± 666.1	0.307	—	—
	0	LG2055	3,671.8 ± 603.0	0.307	—	—
	4	Placebo	3,644.9 ± 517.7	0.531	−142.5 ± 585.5	0.622
	4	LG2055	3,584.3 ± 574.3	0.531	−87.5 ± 672.6	0.622
	8	Placebo	3,692.9 ± 532.0	0.727	−94.4 ± 708.0	0.520
	8	LG2055	3,658.3 ± 589.9	0.727	−13.5 ± 709.0	0.520
	12	Placebo	3,959.8 ± 504.4	0.202	172.5 ± 638.1	0.929
	12	LG2055	3,833.8 ± 606.1	0.202	162.0 ± 687.3	0.929
CD40	0	Placebo	3,729.8 ± 795.5	0.538	—	—
	0	LG2055	3,804.6 ± 538.5	0.538	—	—
	4	Placebo	3,834.1 ± 724.2	0.544	104.3 ± 712.0	0.989
	4	LG2055	3,907.2 ± 624.8	0.544	102.6 ± 668.8	0.989
	8	Placebo	4,220.6 ± 820.3	0.989	490.8 ± 780.4	0.577
	8	LG2055	4,222.5 ± 716.2	0.989	417.8 ± 684.7	0.577
	12	Placebo	4,268.7 ± 765.9	0.799	538.9 ± 827.7	0.467
	12	LG2055	4,235.9 ± 673.0	0.799	431.3 ± 840.9	0.467

^*Significant difference between the two groups (p < 0.05).